173 related articles for article (PubMed ID: 37454339)
1. An International Survey of Allogeneic Hematopoietic Cell Transplantation for X-Linked Agammaglobulinemia.
Nishimura A; Uppuluri R; Raj R; Swaminathan VV; Cheng Y; Abu-Arja RF; Fu B; Laberko A; Albert MH; Hauck F; Bucciol G; Bigley V; Elcombe S; Kharya G; Pronk CJH; Wehr C; Neven B; Warnatz K; Meyts I; Morio T; Gennery AR; Kanegane H
J Clin Immunol; 2023 Nov; 43(8):1827-1839. PubMed ID: 37454339
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.
Ikegame K; Imai K; Yamashita M; Hoshino A; Kanegane H; Morio T; Kaida K; Inoue T; Soma T; Tamaki H; Okada M; Ogawa H
J Hematol Oncol; 2016 Feb; 9():9. PubMed ID: 26873735
[TBL] [Abstract][Full Text] [Related]
3. Treosulfan-based reduced toxicity hematopoietic stem cell transplantation in X-linked agammaglobulinemia: A cost-effective alternative to long-term immunoglobulin replacement in developing countries.
Vellaichamy Swaminathan V; Uppuluri R; Patel S; Melarcode Ramanan K; Ravichandran N; Jayakumar I; Vaidhyanathan L; Raj R
Pediatr Transplant; 2020 Feb; 24(1):e13625. PubMed ID: 31821668
[TBL] [Abstract][Full Text] [Related]
4. Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for
van Zelm MC; Pumar M; Shuttleworth P; Aui PM; Smart JM; Grigg A; Bosco JJ
Front Immunol; 2019; 10():895. PubMed ID: 31105705
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
Nishimura A; Aoki Y; Ishiwata Y; Ichimura T; Ueyama J; Kawahara Y; Tomoda T; Inoue M; Matsumoto K; Inoue K; Hiroki H; Ono S; Yamashita M; Okano T; Tanaka-Kubota M; Ashiarai M; Miyamoto S; Miyawaki R; Yamagishi C; Tezuka M; Okawa T; Hoshino A; Endo A; Yasuhara M; Kamiya T; Mitsuiki N; Ono T; Isoda T; Yanagimachi M; Tomizawa D; Nagasawa M; Mizutani S; Kajiwara M; Takagi M; Kanegane H; Imai K; Morio T
J Clin Immunol; 2021 Jul; 41(5):944-957. PubMed ID: 33527309
[TBL] [Abstract][Full Text] [Related]
7. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity.
Fitch T; Lane A; McDonnell J; Bleesing J; Jordan M; Kumar A; Khandelwal P; Khoury R; Marsh R; Chandra S
Transplant Cell Ther; 2024 Jan; 30(1):101.e1-101.e12. PubMed ID: 37821080
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
9. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
[TBL] [Abstract][Full Text] [Related]
10. [Peripheral blood stem cell transplantation from HLA-mismatched unrelated donor or haploidentical donor for the treatment of X-linked agammaglobulinemia].
Nie L; Su T; Yang KT; Zhao L; Hu J; Yang SH; Xu YJ; Fu B
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Aug; 22(8):821-827. PubMed ID: 32800027
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
[TBL] [Abstract][Full Text] [Related]
12. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
[TBL] [Abstract][Full Text] [Related]
13. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.
Marsh RA; Rao K; Satwani P; Lehmberg K; Müller I; Li D; Kim MO; Fischer A; Latour S; Sedlacek P; Barlogis V; Hamamoto K; Kanegane H; Milanovich S; Margolis DA; Dimmock D; Casper J; Douglas DN; Amrolia PJ; Veys P; Kumar AR; Jordan MB; Bleesing JJ; Filipovich AH
Blood; 2013 Feb; 121(6):877-83. PubMed ID: 23131490
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
[TBL] [Abstract][Full Text] [Related]
16. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
17. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
Khandelwal P; Bleesing JJ; Davies SM; Marsh RA
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic engraftment of XLA bone marrow CD34(+) cells in NOG/SCID mice.
Moreau T; Bardin F; Barlogis V; Le Deist F; Chabannon C; Tonnelle C
Cytotherapy; 2009; 11(2):198-205. PubMed ID: 19235603
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
20. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
